Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 1/20 | 0.61 |
| ▸ | CDK9 | P50750 | 1/20 | 0.61 |
| ▸ | INSR | P06213 | 3/20 | 0.56 |
| ▸ | IGF1R | P08069 | 3/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.56 |
| ▸ | BCL6 | P41182 | 1/20 | 0.56 |
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29833319 | 1.00 | CDK7 (0.61) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL30725504 | 0.87 | BCL6 (0.53) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL11916362 | 0.86 | CDK7 (0.60) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL29400320 | 0.86 | CDK7 (0.60) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL19313060 | 0.85 | CDK7 (0.59) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL26717249 | 0.85 | INSR (0.72) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL25056368 | 0.84 | IGF1R (0.46) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL14240702 | 0.84 | CDK7 (0.58) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL19669895 | 0.83 | CDK7 (0.66) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL23571876 | 0.82 | CDK7 (0.59) | CDK7CDK9INSRIGF1RALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355146-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PHENYL} PYRIMIDINE-2,4-DIAMINE | ARIAD PHARMACEUTICALS, INC. | 2021-11-18 | — | — | US | disclosed |
| US-10934317-B2 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine | ARIAD PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-2844642-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10385078-B2 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine | ARIAD PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180037597-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-08 | — | — | US | disclosed |
| US-20180037597-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-08 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834518-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834518-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| WO-2016000581-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | 南京明德新药研发股份有限公司 | 2016-01-07 | — | — | WO | disclosed |
| EP-2704572-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2013169401-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2012151561-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | BRAF, RAF1, EGFR | CDK7 315/4885CDK9 208/4885INSR 856/4885 |
| US-20210355146-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PHENYL} PYRIMIDINE-2,4-DIAMINE | ERBB2, ERBB4, CDK2 | CDK7 152/4885CDK9 80/4885INSR 1217/4885 |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | CDK7 56/4885CDK9 36/4885INSR 726/4885 |
| US-10385078-B2 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine | ERBB2, ABL1, CDK2 | CDK7 180/4885CDK9 109/4885INSR 1242/4885 |
| US-20180037597-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE | ERBB2, ABL1, ERBB4 | CDK7 231/4885CDK9 149/4885INSR 951/4885 |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | CDK7 56/4885CDK9 36/4885INSR 726/4885 |
| US-10934317-B2 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine | ERBB2, ABL1, CDK2 | CDK7 180/4885CDK9 109/4885INSR 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.